SecBot SecBot
8-K ·Filed Aug 5, 2026

UTHR

UNITED THERAPEUTICS Corp
MIXED
Impact 6/10
Horizonweeks Processed3mo ago SEC0001082554-26-000028
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The mixed quarter, revenue miss with EPS beat, may lead to modest near-term volatility. Key catalysts to watch are the FDA decisions on ralinepag (PAH) and Nebulized Tyvaso (IPF) NDAs, expected by mid-2027. Monitor competitive dynamics in inhaled prostacyclins and Tyvaso DPI's ability to offset Nebulized Tyvaso erosion.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$519.01
T+0 close · Aug 5, 2026 · via day close
Latest settled
+14.09%
T+60 · $592.12
Vs SPY
+13.89%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 5 $519.01entry
  2. T+1 · 3mo ago +2.68%α +2.84% · $532.94
  3. T+5 · 3mo ago −1.40%α −1.76% · $511.72
  4. T+20 · 3mo ago −5.20%α −4.60% · $492.02
  5. T+60 · 19d ago +14.09%α +13.89% · $592.12
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

United Therapeutics reported Q2 2026 revenue of $783.3M, down 2% YoY and below the $804.6M consensus, while diluted EPS of $7.27 beat the $6.86 estimate by 5.9%. The revenue miss was driven by a 4% decline in total Tyvaso sales as Nebulized Tyvaso dropped 18% YoY, partially offset by Tyvaso DPI growth. Net income rose 8% YoY to $333.0M, benefiting from a lower effective tax rate (11% vs 24%) and the absence of a prior-year $21.7M PPE impairment. The company highlighted recent NDA submissions for ralinepag (PAH) and Nebulized Tyvaso (IPF) as key pipeline catalysts, but the top-line decline and competitive headwinds in the inhaled prostacyclin class temper the outlook.

Key Financial Metrics

EPS
$7.27
est $6.86 · +6.0%
Revenue
$783.3M
est $804.6M · -2.6% · -1.9% YoY
Rating
in line

Key Facts

  • Revenue decreased 2% YoY to $783.3M, missing consensus of $804.6M.
  • Diluted EPS of $7.27 beat consensus of $6.86 by 5.9%.
  • Total Tyvaso revenue fell 4% YoY to $452.6M; Nebulized Tyvaso declined 18% to $126.0M.
  • Tyvaso DPI revenue grew 4% YoY to $326.6M, with record patient starts and referrals.
  • Net income increased 8% YoY to $333.0M, aided by a lower effective tax rate of 11% vs 24%.
  • Company submitted NDAs for ralinepag tablets (PAH) and Nebulized Tyvaso (IPF), with potential approvals expected in 2027.
  • Share repurchases totaled 2.76M shares under $1.5B ASR agreements; $500M remains authorized through March 2027.
  • Cash and investments stood at $3.80B as of June 30, 2026.

Financial Impact

Revenue miss of ~$21M vs consensus; EPS beat of $0.41 per share.

revenueepsnet incometax rate

Risk Factors

  • Continued competitive pressure on Nebulized Tyvaso and Remodulin from newer therapies.
  • Regulatory and clinical risks for ralinepag and Tyvaso DPI in IPF/PPF.
  • Potential dilution from share-based compensation and future capital needs for organ manufacturing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001082554-26-000028
Document: uthr-20260805.htm0001082554-26-000028
Document: 0001082554-26-000028-index-headers.html0001082554-26-000028
Document: 0001082554-26-000028-index.html0001082554-26-000028
Document: 0001082554-26-000028.txt0001082554-26-000028
8-K Data (Synthetic)0001082554-26-000028

Track record

123 reports on UTHR

Performance horizon

4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
  2. Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
  3. Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
  4. Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
  5. Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
  6. Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
  7. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
  8. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
  9. Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
  10. Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
Showing 10 of 123

US Market Status

Market Closed · Opens Wed (10h 16m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 5, 2026